{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-004224","form_type":"8-K","ticker":"TCRT","cik":"0001107421","company_name":"Alaunos Therapeutics, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.883088+00:00","generated_at":"2026-06-20T17:29:04.140191+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Alaunos doubles TCR library addressable market; cash runway into Q4 2023","bullets":["Added two new TCRs to library, doubling addressable market; targets KRAS, TP53, EGFR hotspot mutations.","Enrolling patients in TCR-T Phase 1/2; third patient dosed Dec 2022; interim data expected mid-2023.","Manufacturing capacity doubled; moving to cryopreserved product reduces process time 13% (30 to 26 days).","mbIL-15 program IND filing anticipated H2 2023.","Cash $39.1M (unaudited) plus $13.9M restricted; runway into Q4 2023; operating cash flow $35-40M in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-004224","json":"https://secwatch.observer/filing/0001193125-23-004224.json","markdown":"https://secwatch.observer/filing/0001193125-23-004224.md","text":"https://secwatch.observer/filing/0001193125-23-004224.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1107421/000119312523004224/0001193125-23-004224-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1107421/000119312523004224/d410539d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:29:04.140191+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}